CliffBio
small molecule

BRIVIACT

BRIVARACETAM

Loss of exclusivityFebruary 2026latest FDA-listed patent expiry
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameBRIVIACT
Active ingredientBRIVARACETAM
Strength50MG/5ML (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusRX

Listed patents

PatentExpiresType
6911461February 2026substance, product

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BRIVIACT patent cliff — loss of exclusivity February 2026 | CliffBio